Theralase Technologies Inc (CVE:TLT, OTCMKTS:TLTFF) has now advanced to the second phase of its Phase Ib clinical trial for non-muscle invasive bladder cancer using lead cancer compound TLD-1433.
As reported last week, the treatment of the first three patients at the maximum recommended starting dose ("MRSD") of the 0.35 mg/cm2 was a resounding success.
The trial also achieved the primary, secondary and exploratory endpoints at the 90 day analysis point.
Now, on July 20, the firm said it had treated the fourth patient with a therapeutic dose (0.70 milligram per cubic centimetre)
"The company is pleased that it has successfully executed on the first part of the study and has now advanced to the second part of the study; specifically, the enrollment and treatment of an additional 6 patients at the Therapeutic Dose of the PDC," said Roger Dumoulin-White, Theralase's president and chief executive.
"Theralase looks forward to successfully executing on the second part of the study and will report out on its progress, as appropriate," he added.
TLD - 1433 is a light activated photo dynamic compound (PDC), which the firm is developing, and the trial is the first part of a Phase Ib clinical study for patients with non-muscle invasive bladder cancer (NMIBC).
Shares in Toronto eased 1.02% to 48 cents.